透明质酸精子选择改善高龄夫妇活产结局并与精子DNA质量相关,可能影响所有治疗结局
HABSelect 3期随机对照试验纳入2752对夫妇,比较ICSI前透明质酸结合/选择精子与常规ICSI。机制分析选取1247份精液样本,发现高龄女性随机至PICSI组活产率与年轻女性相同;HBS与DNAq指标相关,模型显示治疗分配与活产相关。
要点
- 高龄女性随机至PICSI组活产率与年轻女性相同,可能因更好避免DNA损伤精子。
- HBS与AO、Comet、TUNEL负相关,与SCD正相关(均P<0.001)。
- PICSI降低受精率且未改善累积妊娠率。
核心结论
- 高龄女性随机至PICSI组活产率与年轻女性相同,最可能因更好避免DNA损伤精子。
- 精子DNA质量差(以较低HBS反映)可能降低所有妊娠结局包括活产。
- 作者认为,HA选择精子用于ICSI可考虑作为高龄助孕患者治疗计划的一部分。
研究设计与样本
- HABSelect为3期随机对照试验,2014至2017年纳入2752对夫妇,精液样本冷冻保存用于DNA质量评估。
- 机制研究组2016至2018年运行,从试验招募队列中抽取1247份样本进行回顾性分析,故意富集流产结局(n=92或7.4%),全部2752对夫妇中流产154例(5.6%)。
- 新鲜精液样本在治疗日经密度梯度离心或(少数)上游法处理前获取精子浓度、前向运动百分比和HA结合评分(HBS)。
主要发现
- 所有HBS和DNAq指标均能区分正常与异常精液样本(P<0.001)。
- SCD与Comet负相关(r=-0.165;P<0.001),与TUNEL负相关(r=-0.200;P<0.001)。
- HBS与AO负相关(r=-0.211;P<0.001)、与Comet负相关(r=-0.127;P<0.001)、与TUNEL负相关(r=-0.214;P<0.001),与SCD正相关(r=0.255;P<0.001)。
- 预测生化妊娠率的模型包括男性年龄(每十年OR 0.464,95%CI 0.314-0.674,P<0.001)和SCD assay(每升高10分OR 1.04,95%CI 1.007-1.075,P=0.018)。
关键数值与推荐
- HBS和DNAq所有指标均能区分正常与异常精液样本(P<0.001)。
- 预测活产模型:治疗分配OR 2.167(95%CI 1.084-4.464,P=0.031)。
- 预测生化妊娠模型:男性年龄每十年OR 0.464(95%CI 0.314-0.674,P<0.001)。
临床怎么用
- 作者认为,HA选择精子用于ICSI可考虑作为高龄助孕患者治疗计划的一部分。
- PICSI降低受精率且未改善累积妊娠率。
局限性
- HABSelect为前瞻性随机对照试验,但机制研究组来自其招募队列进行回顾性分析,未完全受益于随机化。
- DNAq指标来自残余样本而非HA选择与未选择精子,临床与机制部分互斥。
- 为补偿DNAq数据质量变异,开发了将机制数据与基线及其他临床数据拟合的模型。
- HABSelect使用固态PICSI,未评估任何液态替代方案的疗效。
- PICSI降低受精率且未改善累积妊娠率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What effects did treatment using hyaluronic acid (HA) binding/selection prior to ICSI have on clinical outcomes in the Hyaluronic Acid Binding sperm Selection (HABSelect) clinical trial? SUMMARY ANSWER: Older women randomized to the trial's experimental arm (selection of sperm bound to immobilized (solid-state) HA) had the same live birth rates as younger women, most likely a result of better avoidance of sperm with damaged DNA. WHAT IS KNOWN ALREADY: Recent randomized controlled trials (RCTs) investigating the efficacy of HA-based sperm selection prior to ICSI, including HABSelect, have consistently reported reductions in the numbers of miscarriages among couples randomized to the intervention, suggesting a pathological sperm-mediated factor mitigated by prior HA-binding/selection. The mechanism of that protection is unknown. STUDY DESIGN, SIZE, DURATION: The original HABSelect Phase 3 RCT ran from 2014 to 2017 and included 2752 couples from whom sperm samples used in control (ICSI) and intervention (Physiological IntraCytoplasmic Sperm Injection; PICSI) arms of the trial were stored frozen for later assessment of DNA quality (DNAq). The trial overlapped with its mechanistic arm, running from 2016 to 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: As miscarriage reduction was a significant secondary outcome of the trial, samples (n = 1247) selected for the mechanistic analysis were deliberately enriched for miscarriage outcomes (n = 92 or 7.4%) from a total of 154 miscarriages (5.6%) among all (n = 2752) couples randomized by stratified random sampling. Values from fresh semen samples for sperm concentration (mml), percentage forward progressive motility and percentage HA-binding score (HBS) were obtained before being processed by differential density gradient centrifugation or (rarely) by swim-up on the day of treatment. Surplus sperm pellets were recovered, aliquoted and cryopreserved for later analysis of DNAq using slide-based Comet, TUNEL, acridine orange (AO) and the sperm chromatin dispersion (SCD) assays. Following their classification into normal and abnormal sample subcategories based on reference values for sperm concentration and motility, relationships with HBS and DNAq were examined by Spearman correlation, Student's t-tests, Mann Whitney U tests, and logistic regression (univariable and multivariable). Parsimonious selection enabled the development of models for exploring and explaining data trends. Potential differences in future cumulative pregnancy rates relating to embryo quality were also explored. MAIN RESULTS AND THE ROLE OF CHANCE: Results from the 1247 sperm samples assayed for HBS and/or DNAq, generated data that were considered in relation to standard physiological measures of (sperm) vitality and to treatment outcomes. All measures of HBS and DNAq discriminated normal from abnormal sperm samples (P < 0.001). SCD correlated negatively with the Comet (r = -0.165; P < 0.001) and TUNEL assays (r = -0.200; P < 0.001). HBS correlated negatively with AO (r = -0.211; P < 0.001), Comet (r = -0.127; P < 0.001) and TUNEL (r = -0.214; P < 0.001) and positively with SCD (r = 0.255; P < 0.001). A model for predicting live birth (and miscarriage) rates included treatment allocation (odds ratio: OR 2.167, 95% CI 1.084-4.464, P = 0.031), female age (OR 0.301, 95% CI 0.133-0.761, P = 0.013, per decade) and the AO assay (OR 0.79, 95% CI 0.60-1. 02.761, P = 0.073, per 10 points rise). A model predicting the expected rate of biochemical pregnancy included male age (OR 0.464, 95% CI 0.314-0.674, P < 0.001, per decade) and the SCD assay (OR 1.04, 95% CI 1.007-1.075, P = 0.018, per 10 point rise). A model for conversion from biochemical to clinical pregnancy did not retain any significant patient or assay variables. A model for post-injection fertilization rates included treatment allocation (OR 0.83, 95% CI 0.75-0.91, P < 0.001) and the Comet assay (OR 0.950, 95% CI 0.91-1.00, P = 0.041). LIMITATIONS, REASONS FOR CAUTION: HABSelect was a prospective RCT and the mechanistic study group was drawn from its recruitment cohort for retrospective analysis, without the full benefit of randomization. The clinical and mechanistic aspects of the study were mutually exclusive in that measures of DNAq were obtained from residual samples and not from HA-selected versus unselected sperm. Models for fitting mechanistic with baseline and other clinical data were developed to compensate for variable DNAq data quality. HABSelect used a solid-state version of PICSI and we did not assess the efficacy of any liquid-state alternatives. PICSI reduced fertilization rates and did not improve the outlook for cumulative pregnancy rates. WIDER IMPLICATIONS OF THE FINDINGS: Notwithstanding the interventional effect on fertilization rates and possibly blastocyst formation (neither of which influenced pregnancy rates), poor sperm DNAq, reflected by lower HBS, probably contributed to the depression of all gestational outcomes including live births, in the HABSelect trial. The interventional avoidance of defective sperm is the best explanation for the equalization in live birth rates among older couples randomized to the trial's PICSI arm. As patients going forward for assisted conception cycles globally in future are likely to be dominated by an older demographic, HA-based selection of sperm for ICSI could be considered as part of their treatment plan. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by the National Institute for Health Research (NIHR) EME (Efficacy and Mechanism Evaluation)-11-14-34. National Research Ethics Service approval 11/06/2013: 13/YH/0162. S.L. is CEO of ExamenLab Ltd (company number NI605309). TRIAL REGISTRATION NUMBER: ISRCTN99214271.
引用
- West R, Coomarasamy A, Frew L, et al. Sperm selection with hyaluronic acid improved live birth outcomes among older couples and was connected to sperm DNA quality, potentially affecting all treatment outcomes. Hum Reprod. 2022. PMID: 35459947. doi:10.1093/humrep/deac058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。